An aqueous based formulation for a personal care product, that relies upon the use of fulvic-humic acid and/or humic acid, which acid(s) are present at a level of 0.01 wt. % to 10.0 wt. % and activated carbon black at a level of 5.0 wt. %.

Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

Compositions with fulvate fractions alone or in combination with growth factors, bioactive fragmented peptides, or combinations thereof are disclosed herein. Also disclosed are methods of using said compositions for the catalyzing cellular regeneration, including the healing, treatment, or prevention of skin disorders. Also disclosed are methods for extracting, isolating, and purifying fulvate fractions for use in the manufacture of said compositions.

In some embodiments, a composition and/or method may include a toxin binding system formulated for safe and effective mixture into various feed rations which are fed to monogastric and ruminant animals such as poultry, swine, cows, cattle, and fish, among others. The toxin binding system includes novel combinations of one or more of an organoclay, an activated hydrated sodium calcium aluminosilicate clay, and a synthetic hectorite clay. In some embodiments, the binding composition may include organoclay, bentonite, hectorite, Leonardite, and/or any combination thereof. The toxin binding complex may effectively bind mycotoxins, endotoxins and some pesticides in the animal's digestive system, preventing their absorption and the consequent damages to the animal. This binding action includes the T-2 toxin, which can start their damaging action in the animal's mouth, hence, offering protection from oral lesions.

In some embodiments, a composition and/or method may include a toxin binding system formulated for safe and effective mixture into various feed rations which are fed to monogastric and ruminant animals such as poultry, swine, cows, cattle, and fish, among others. The toxin binding system includes novel combinations of one or more of an organoclay, an activated hydrated sodium calcium aluminosilicate clay, and a synthetic hectorite clay. In some embodiments, the binding composition may include organoclay, bentonite, hectorite, Leonardite, and/or any combination thereof. The toxin binding complex may effectively bind mycotoxins, endotoxins and some pesticides in the animal's digestive system, preventing their absorption and the consequent damages to the animal. This binding action includes the T-2 toxin, which can start their damaging action in the animal's mouth, hence, offering protection from oral lesions.

In some embodiments, a composition and/or method may include a toxin binding system formulated for safe and effective mixture into various feed rations which are fed to monogastric and ruminant animals such as poultry, swine, cows, cattle, and fish, among others. The toxin binding system includes novel combinations of one or more of an organoclay, an activated hydrated sodium calcium aluminosilicate clay, and a synthetic hectorite clay. In some embodiments, the binding composition may include organoclay, bentonite, hectorite, Leonardite, and/or any combination thereof. The toxin binding complex may effectively bind mycotoxins, endotoxins and some pesticides in the animal's digestive system, preventing their absorption and the consequent damages to the animal. This binding action includes the T-2 toxin, which can start their damaging action in the animal's mouth, hence, offering protection from oral lesions.

In some embodiments, a composition and/or method may include a rodenticide binding system formulated for safe and effective mixture into various feed rations which are fed to monogastric and ruminant animals such as poultry, swine, cows, cattle, and fish, among others. The rodenticide binding system includes novel combinations of one or more of an organoclay, an activated hydrated sodium calcium aluminosilicate clay, and a synthetic hectorite clay. In some embodiments, the binding composition may include organoclay, bentonite, hectorite, Leonardite, and/or any combination thereof. The toxin binding complex may effectively bind some pesticides (e.g., rodenticides) in the animal's digestive system, preventing their absorption and the consequent damages to the animal.

In some embodiments, a composition and/or method may include a rodenticide binding system formulated for safe and effective mixture into various feed rations which are fed to monogastric and ruminant animals such as poultry, swine, cows, cattle, and fish, among others. The rodenticide binding system includes novel combinations of one or more of an organoclay, an activated hydrated sodium calcium aluminosilicate clay, and a synthetic hectorite clay. In some embodiments, the binding composition may include organoclay, bentonite, hectorite, Leonardite, and/or any combination thereof. The toxin binding complex may effectively bind some pesticides (e.g., rodenticides) in the animal's digestive system, preventing their absorption and the consequent damages to the animal.

The present invention discloses a medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, a preparation method thereof and use methods thereof. The medicine comprises: lightyellow sophora root, glabrous greenbrier rhizome, bark of Chinese corktree, raw sessile stemona root, alumen, coptis root, cortex dictamni, chinaberry bark and root-bark, pangolin scales, amber, eucommia bark, tree peony bark, clematis root, common cnidium fruit, Chinese angelica, licorice root, common macrocarpium fruit, barbary wolfberry fruit, medicinal indianmulberry root, cherokee rose fruit, chinaroot greenbier rhizome, akebia fruit, milkvetch root, Japanese climbing fern spore, asiatic pennywort herb, mulberry leaf and frankincense. The present invention not only provides the medicine capable of effectively treating the acquired immunodeficiency syndrome, but also enables the medicine to be capable of being used in conjunction with other medical technical means to easily achieve a more ideal treatment effect.